PMID- 26031284
OWN - NLM
STAT- MEDLINE
DCOM- 20160315
LR  - 20181113
IS  - 1435-1250 (Electronic)
IS  - 0340-1855 (Linking)
VI  - 74
IP  - 5
DP  - 2015 Jun
TI  - [Treatment strategies for ANCA-associated vasculitides].
PG  - 388-97
LID - 10.1007/s00393-014-1532-7 [doi]
AB  - BACKGROUND: Recent data from randomized controlled clinical trials have allowed 
      the development of recommendations for treatment of anti-neutrophil cytoplasmic 
      antibody (ANCA) associated vasculitides (AAV). METHODS: A selective literature 
      search was carried out for studies and recommendations for treatment of AAV. 
      RESULTS: In active severe AAV a combination of prednisolone and cyclophosphamide 
      or rituximab leads to a therapeutic response in approximately 90 % of cases. Once 
      remission is attained the administration of azathioprine or methotrexate for 2-4 
      years is required for maintenance of remission. Relapse occurs in more than 30 % 
      of patients despite maintenance treatment. In cases of persistence or progression 
      of disease activity during standard therapy, referral to an expert center should 
      be considered. Despite improvement in the prognosis in recent years early 
      mortality is increased, particularly due to infections. CONCLUSION: Stage and 
      activity adapted treatment strategies have improved the outcome of AAV in the 
      past three decades. The elevated early mortality and the risk of relapse show the 
      need for further improvement of current treatment protocols with respect to 
      substance selection, dosage of glucocorticoids and immunosuppressants and the 
      duration of therapy.
FAU - Hellmich, B
AU  - Hellmich B
AD  - Klinik fur Innere Medizin, Rheumatologie und Immunologie, Vaskulitiszentrum Sud 
      Tubingen-Kirchheim, Klinikum Kirchheim, Akademisches Lehrkrankenhaus der 
      Universitat Tubingen, Eugenstr. 3, 73230, Kirchheim-Teck, Deutschland, 
      b.hellmich@kk-es.de.
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Therapeutisches Vorgehen bei ANCA-assoziierten Vaskulitiden.
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis/*drug 
      therapy
MH  - Antirheumatic Agents/*administration & dosage
MH  - *Drug Administration Schedule
MH  - Evidence-Based Medicine
MH  - Glucocorticoids/*administration & dosage
MH  - Humans
MH  - Immunosuppressive Agents/*administration & dosage
MH  - Treatment Outcome
EDAT- 2015/06/03 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/06/03 06:00
PHST- 2015/06/03 06:00 [entrez]
PHST- 2015/06/03 06:00 [pubmed]
PHST- 2016/03/16 06:00 [medline]
AID - 10.1007/s00393-014-1532-7 [doi]
PST - ppublish
SO  - Z Rheumatol. 2015 Jun;74(5):388-97. doi: 10.1007/s00393-014-1532-7.